Previous 10 | Next 10 |
2024-07-09 07:00:00 ET Summary Biotech indexes lagged broader market indexes in the first half of 2024, and trade at the same level as in early 2022. Biotech valuations are closely tied to the Fed's interest rate policy and are highly correlated to the 10-year yield. Inflation...
2024-07-06 07:45:00 ET Summary ClearBridge is a leading global asset manager committed to active management. Research-based stock selection guides our investment approach, with our strategies reflecting the highest-conviction ideas of our portfolio managers. During the quarter, a ...
2024-07-06 04:15:00 ET Vertex Pharmaceuticals (NASDAQ: VRTX) transformed the world of cystic fibrosis (CF) treatment when it launched its first product for the disease 12 years ago. Since then, it's built a CF treatment empire, including a portfolio of products that actually address...
2024-07-05 07:45:00 ET Investing in equity markets is a reliable, wealth-growing strategy. In the past 33 years, the S&P 500 's average annual return is about 10.6%. It's hard to find a return much better than that elsewhere. Some individual stocks have performed even better, th...
2024-07-05 05:45:00 ET With Vertex Pharmaceuticals (NASDAQ: VRTX) announcing on June 21 that its therapy VX-880 helped nearly all of the patients with diabetes in a clinical trial to reduce or eliminate their need for other treatments, it's natural for investors to assume that Nov...
2024-07-02 08:58:53 ET Vertex Pharmaceuticals ( NASDAQ: VRTX ) has been granted FDA priority review for its investigational once-daily vanza triple combination treatment for cystic fibrosis, with a target action date set for January 2, 2025.... Read the full article on See...
- Vanza triple granted priority review with Prescription Drug User Fee Act (PDUFA) target action date of January 2, 2025 – - EU Marketing Authorization Application (MAA) submission also validated by European Medicines Agency (EMA) Vertex Pharmaceuticals Incorporated (...
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its second quarter 2024 financial results on Thursday, August 1, 2024 after the financial markets close. The company will host a conference call and webcast at 4:30 p.m. ET. To access the call, please dial (833) 630-2124 (U.S.) or +...
2024-06-29 11:35:00 ET The Health Care Select Sector SPDR Fund ETF ( NYSEARCA: XLV ), tracking the healthcare companies under S&P 500, rose 0.11% in the second quarter of 2024, lagging behind the broader S&P 500 index which rose 4.30%.... Read the full article on Seeki...
2024-06-28 07:45:00 ET The stock market has its ups and downs -- and if you stay invested for decades, you will likely experience your fair share of both bull and bear markets. At the same time, by investing in a diverse assortment of stocks across various industries, risk profiles, and bus...
News, Short Squeeze, Breakout and More Instantly...
Vertex Pharmaceuticals Incorporated Company Name:
VRTX Stock Symbol:
NASDAQ Market:
Vertex Pharmaceuticals Incorporated Website:
Health Canada Grants Marketing Authorization for TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) for People With Cystic Fibrosis Aged 2 Years and Older With Certain Rare Mutations Canada NewsWire -Approximately 200 people with certain rare CF mutations are now ...